Table 1.
Outcome | Ondansetron (N = 19) |
Placebo (N = 22) |
||
---|---|---|---|---|
LL (N = 7) | LS/SS (N = 12) | LL (N = 7) | LS/SS (N = 15) | |
Age in years | 54.143 (8.764) | 52.083 (16.572) | 49.571 (14.547) | 54.600 (12.988) |
Sex, no. (%) | ||||
Male | 3 (43) | 9 (75) | 4 (57) | 13 (93) |
Female | 4 (57) | 3 (25) | 3 (43) | 1 (7) |
Race/ethnicity, no. (%) | ||||
White | 7 (100) | 12 (100) | 7 (100) | 13 (87) |
Hispanic | – | – | – | 2 (13) |
Self-reported drinks/drinking day† | 0.540 (0.183) | 0.625 (0.438) | 0.535 (0.558) | 0.506 (0.864) |
Mean baseline expression | 1.550 (0.593) | 1.454 (0.605) | 1.410 (0.724) | 1.660 (0.514) |
Breath alcohol concentration, % | 0.000 | 0.000 | 0.000 | 0.003 (0.010) |
Age of alcoholism onset in years | 43.600 (16.906) | 38.000 (17.311) | 30.714 (10.610) | 36.583 (19.528) |
Social class, no. (%)‡ | ||||
1–3 | 4 | 8 | 5 | 9 |
4–6 | 2 | 4 | 2 | 4 |
7–9 | 1 | – | – | 1 |
Body mass index, kg/m2 | 17.122 (3.594) | 26.405 (12.858) | 22.997 (12.700) | 17.841 (4.685) |
*Values are expressed as mean (SD) unless otherwise indicated. All values were collected at the screening visit.
† Reflects mean values during the 90-day period preceding the screening visit.
‡Defined by Hollingshead and Redlich (1958).